FDA Accepts New Drug Application for Gedatolisib in PIK3CA Wild-Type Breast Cancer
Written by
Cancer Network
Published
0
comments
0
min
The rolling submission is supported by data from the PIK3CA wild-type cohort of the phase 3 VIKTORIA-1 trial evaluating gedatolisib in advanced breast cancer.